- Home
- JGH vs MGTX Comparison
JGH vs MGTX Comparison
Compare JGH & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- MGTX
- Stock Information
- Founded
- JGH 2014
- MGTX 2015
- Country
- JGH United States
- MGTX United States
- Employees
- JGH N/A
- MGTX N/A
- Industry
- JGH Investment Managers
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JGH Finance
- MGTX Health Care
- Exchange
- JGH Nasdaq
- MGTX Nasdaq
- Market Cap
- JGH 304.1M
- MGTX 411.4M
- IPO Year
- JGH N/A
- MGTX N/A
- Fundamental
- Price
- JGH $12.97
- MGTX $5.98
- Analyst Decision
- JGH
- MGTX Strong Buy
- Analyst Count
- JGH 0
- MGTX 2
- Target Price
- JGH N/A
- MGTX $22.50
- AVG Volume (30 Days)
- JGH 73.9K
- MGTX 325.1K
- Earning Date
- JGH 01-01-0001
- MGTX 11-12-2024
- Dividend Yield
- JGH 9.85%
- MGTX N/A
- EPS Growth
- JGH N/A
- MGTX N/A
- EPS
- JGH N/A
- MGTX N/A
- Revenue
- JGH N/A
- MGTX $8,122,000.00
- Revenue This Year
- JGH N/A
- MGTX $133.83
- Revenue Next Year
- JGH N/A
- MGTX $655.34
- P/E Ratio
- JGH N/A
- MGTX N/A
- Revenue Growth
- JGH N/A
- MGTX 26.87
- 52 Week Low
- JGH $10.36
- MGTX $3.49
- 52 Week High
- JGH $12.85
- MGTX $7.60
- Technical
- Relative Strength Index (RSI)
- JGH 38.66
- MGTX 78.17
- Support Level
- JGH $12.99
- MGTX $3.97
- Resistance Level
- JGH $13.15
- MGTX $6.24
- Average True Range (ATR)
- JGH 0.11
- MGTX 0.33
- MACD
- JGH -0.05
- MGTX 0.20
- Stochastic Oscillator
- JGH 13.73
- MGTX 88.56
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.